Insights from Real Hospitals: The Margin-Enhancing Benefits of Patient Safety
We recently released results from an economic value assessment of clinical surveillance by healthcare consultancy Sage Growth Partners. The results were extremely exciting, but not surprising to us here at VigiLanz, nor to our customers.
The assessment found that most hospitals could save millions of dollars by implementing VigiLanz.
For more on how the assessment was created, check out our economic value calculator. And, to learn how much your hospital could save, use the calculator to receive an instant, customized analysis. The tool requires you to input only a few data points, such as annual inpatient admissions, number of staffed beds, and daily census.
Hundreds of hospitals across the country can attest to the margin-improving benefits of VigiLanz. For example, we help hospitals identify IV to PO conversion opportunities; enhance management of high-cost drugs; and prevent costly events such as hospital acquired infections, adverse drug events, and readmissions.
Here are a few examples of hospitals experiencing significant savings due to VigiLanz:
Freeman Health System, a 485-bed, three-hospital system in Missouri, uses VigiLanz to support and streamline its medication reconciliation efforts. Since adopting the new approach, Freeman has completed an average of 1,400 medication reconciliations monthly. This has prevented nearly 30 potential major adverse drug events and more than 11,000 potential minor adverse events over a one-year period. The health system estimates that it has realized $4.7 million in savings from major and minor medication error prevention since July 2018.
Pharmacists at Houston Methodist health system, which encompasses seven hospitals, eight emergency care centers, and a network of more than 7,000 physicians, are using VigiLanz to streamline workflows and communication related to antibiotic use, and to better track and monitor antimicrobial stewardship initiatives. For example, pharmacists receive real-time alerts from VigiLanz whenever rapid diagnostic test results come back positive for gram-negative bloodstream infections. This new workflow has significantly improved patient care, with benefits that include shorter lengths of stay and a 43 percent cost reduction in mean hospital costs per patient (costs fell from $45,709 to $26,162 per patient), according to a Houston Methodist study published in the Archives of Pathology & Laboratory Medicine.
Pharmacists at the 420-bed hospital in California are using VigiLanz for several purposes, including to increase the capture of grouped antimicrobial-related interventions. As a result, the hospital’s cost savings increased from $2.8 million in 2016 to more than $3.6 million in 2017. The hospital also uses VigiLanz to progressively eliminate inappropriate antimicrobial use and reduce days of exposure. The hospital also estimated cost savings due to avoidance of adverse events at more than $576,000 in 2017. In 2016 and 2017, the emergency department alone documented more than $100,000 in savings.
Healthcare providers at the nonprofit community-based health system in California are using VigiLanz’s real-time alerts to flag issues related to antibiotic prescribing—for example, if there is a mismatch between the medication ordered and the patient’s condition. The continued focus on appropriate use of antibiotics, and on the de-escalation of antibiotic use when appropriate, has improved patient care and led to significant cost reductions. The hospital is now meeting national standards for antibiotic utilization, and annual antibiotic usage expenditures have fallen $500,000 per year.
New Report Looks at the Future of Patient Safety
Dr. Hayley Burgess discusses patient safety challenges, improvement opportunities, and the role that technology can play in advancing positive changes in a new article from Patient Safety & Quality Healthcare.
VigiLanz Backs Safer Care: Answering the PCAST Call
VigiLanz stands ready to support the recommendations for improving patient safety as outlined by the President’s Council of Advisors on Science and Technology (PCAST).